10:31 AM EDT, 07/23/2024 (MT Newswires) -- Ainos (AIMD) said Tuesday it enrolled the first subject in its Taiwanese clinical trial of a VELDONA-based animal drug for treating feline chronic gingivostomatitis.

The first subject is scheduled to receive the dose on Friday, the company said. FCGS is a severe and painful chronic oral disease in cats, marked by inflammation or abnormal tissue growth in the mouth.

The randomized, double-blind, single-center trial is expected to test the safety, tolerability, and efficacy of low-dose oral interferons for FCGS, Ainos said.

The company plans to enroll 30 subjects by the end of 2024 with the trial report expected in Q1 2025.

Shares of Ainos rose 4.1% in recent Tuesday trading.

Price: 0.74, Change: +0.03, Percent Change: +4.08